NVST · Envista Holdings Corp
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. Envista posted Q2 2026 core sales growth of 5%, adjusted EBITDA up 28%, and adjusted EPS up 58%, with margin expansion of 230 bps, and raised full-year 2026 guidance for core growth, adjusted EBITDA, and adjusted EPS.
- + Adjusted EPS grew 58% to $0.41 driven by margin gains and a lower tax rate of about 26% for the full year.
- + Strong free cash flow of $105 million in Q2 and 158% conversion supports continued capital return including 2.4 million shares repurchased at ~$24 average.
- + Equipment & Consumables posted 8.5% core growth with adjusted operating profit up 25% and margin up 250 bps.
- − Brackets and wires declined high single digits in Q2 due to a tough prior-year comp from pull-forward demand ahead of tariff/price actions.
- − Guidance implies Q4 core growth to be flat to slightly down due to a four fewer billing days in Q4 versus Q4 2025.
- − Tariff costs rose $5 million versus Q2 2025 and will continue into the second half with Section 301 levies replacing prior tariffs.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NVST
this stock
Envista Holdings Corp
|
$3.85B | +8.1% | -0.1% | 41.3 | 6.4% |
|
ISRG
Intuitive Surgical Inc
|
$143.14B | -28.2% | +20.5% | 46.5 | 2.3% |
|
BDX
Becton Dickinson & Co
|
$49.57B | — | +8.2% | — | 4.2% |
|
MDLN
Medline Inc.
|
$45.62B | -17.4% | +11.5% | — | 3.1% |
|
RMD
Resmed Inc
|
$32.02B | -8.2% | +13.4% | 21.3 | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NVST | -1.5% | -11.9% | -12.0% | -13.5% | +8.1% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -0.8% | -12.0% | -24.2% | -12.9% | -3.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.